Table 1.
Baseline characteristics by baseline body mass index (BMI) subgroup
| Characteristic | BMI <25 kg/m2 | BMI 25–<30 kg/m2 | BMI ≥30 kg/m2 | P value* | ||||||
| PBO (n=79) |
LIXI (n=104) |
Total (n=183) |
PBO (n=142) |
LIXI (n=134) |
Total (n=276) |
PBO (n=42) |
LIXI (n=54) |
Total (n=96) |
||
| Age, years | 56.0±9.9 | 54.3±9.9 | 55.0±9.9 | 55.1±9.1 | 53.4±9.4 | 54.3±9.3 | 50.2±7.7 | 51.2±10.5 | 50.8±9.4 | 0.001 |
| Male, n (%) | 40 (50.6) | 51 (49.0) | 91 (49.7) | 76 (53.5) | 83 (61.9) | 159 (57.6) | 23 (54.8) | 18 (33.3) | 41 (42.7) | 0.028 |
| HbA1c, % | 7.9±0.7 | 8.0±0.7 | 8.0±0.7 | 8.0±0.7 | 8.0±0.8 | 8.0±0.8 | 8.1±0.8 | 8.0±0.8 | 8.1±0.8 | 0.559 |
| Duration of diabetes, years | 10.6±6.1 | 11.2±6.6 | 11.0±6.4 | 10.4±6.3 | 10.0±6.0 | 10.2±6.1 | 8.6±6.6 | 9.2±6.5 | 9.0±6.6 | 0.044 |
| Duration of basal insulin, years† | 2.3±2.4 | 2.5±3.0 | 2.4±2.8 | 2.5±2.7 | 2.0±2.4 | 2.3±2.5 | 1.7±1.7 | 2.3±2.6 | 2.1±2.2 | 0.577 |
| FPG, mmol/L | 6.8±1.8 | 7.1±2.3 | 7.0±2.1 | 6.7±1.8 | 7.1±2.2 | 6.9±2.0 | 7.1±2.1 | 6.9±1.7 | 7.0±1.9 | 0.921 |
| 2-hour PPG, mmol/L | 14.1±3.4 | 14.7±4.9 | 14.4±4.3 | 14.2±3.9 | 13.9±4.2 | 14.1±4.0 | 14.1±3.8 | 12.9±3.8 | 13.4±3.8 | 0.143 |
| Basal insulin dose, U/day | 30.7±11.6 | 33.3±13.5 | 32.2±12.7 | 38.1±15.1 | 37.4±16.2 | 37.8±15.6 | 52.2±31.4 | 50.1±22.4 | 51.0±26.6 | <0.001 |
| Basal insulin dose, U/day/kg | 0.5±0.2 | 0.6±0.2 | 0.5±0.2 | 0.5±0.2 | 0.5±0.2 | 0.5±0.2 | 0.6±0.3 | 0.6±0.3 | 0.6±0.3 | 0.154 |
| BMI, kg/m2 | 23.0±1.3 | 23.2±1.3 | 23.2±1.3 | 27.4±1.5 | 27.1±1.4 | 27.2±1.5 | 33.4±2.5 | 32.9±2.5 | 33.1±2.5 | |
| Body weight, kg | 61.9±7.4 | 61.6±7.4 | 61.7±7.4 | 73.0±9.9 | 73.5±9.7 | 73.2±9.8 | 89.4±10.5 | 85.3±11.8 | 87.1±11.4 | |
All values are given as mean±SD unless otherwise stated.
*P value for differences between total participants of the different BMI subgroups.
†Only available for GetGoal-L and GetGoal-L-C Studies.
FPG, fasting plasma glucose; HbA1c, glycated hemoglobin; LIXI, lixisenatide; PBO, placebo; PPG, postprandial glucose.